Company intelligence / Profile preview

Axiom Partners

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Axiom Therapeutics is a TechBio company focused on discovering and developing novel covalent drugs for "undruggable" targets. Headquartered in London and founded by University of Cambridge PhDs, the company leverages its TrueBond platform—a combination of machine learning and advanced physics simulations—to rationally design precise therapies for conditions such as pancreatic cancer, neurodegeneration, and immunology. Axiom is building a diverse internal pipeline of small molecule covalent inhibitors while also exploring strategic partnerships with major pharmaceutical companies to bring its candidates into clinical trials.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Small moleculeCovalent drugs
Industry: Biotech

Beyond the preview

Go deeper on Axiom Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axiom Partners.

Explore the full profile